List of Personalized Medicine Companies in Massachusetts - 32

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression. Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

AbBC is a next generation ADC company that utilizes a biological conjugation process to target and deliver Granzyme B to cells for internalization and irreversible toxicity without the requirement of cleavage. Our pipeline of 7 fully human fusion proteins in ongoing preclinical development demonstrate inhibition and regression of tumor growth without toxicity. The platform enables the opportunity to methodically select ADC targets for development of new Granzyme B fusion proteins with major focus in oncology.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Anodyne is a venture-backed, clinical-stage biotech company focused on simplifying chronic care for all stakeholders. We specialize in the transdermal delivery of multi-milligram doses and complex formulations, enabling easier access to both existing therapies and emerging large molecule treatments. The HeroPatch, our proprietary technology represents a breakthrough in drug delivery. By transdermally delivering large molecules, it enables tunable pharmacokinetic profiles, new formulations using APIs in dry form, room temperature stability, and combination therapies of next-generation therapeutics. Our product pipeline is dedicated to addressing the unmet needs of chronic diseases, with an initial focus on obesity. We are committed to delivering innovative solutions that significantly impact patients' lives. Anodyne is actively expanding its pipeline through both internal clinical development and strategic external partnerships, maximizing the commercial potential and clinical impact of our advanced drug delivery platform.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

CELLINK is proud to be a part of BICO, the world's leading bioconvergence company. By releasing the first universal bioink in 2016, CELLINK democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. The company's best-in-class bioinks, bioprinters, software and services are trusted by the foremost academics in a range of applications, from 3D cell culturing to tissue engineering to drug development, and have been cited in over 700 publications. Furthermore, more than 1,000 laboratories, including ones at the top 20 pharmaceutical companies, are using these award-winning innovations. As part of BICO's bioconvergence revolution, CELLINK is dedicated to making the on-demand bioprinting of human organs and tissues a future reality and creating the future of health.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

Formerly called Bioline, now acquired by Meridian Bioscience, as part of Meridian Life Science business unit, was founded in 1992 and based in London, UK. Meridian Bioscience is a fully integrated company with two business units dedicated to diagnostics and life science. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Meridian Life Science unit,with large-scale manufacturing capabilities and over 3500 products, provides the most comprehensive portfolio of raw materials for the clinical development of any immunological or molecular test. Our molecular reagents are used by biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology to food and agriculture technology as well as forensic and environmental sciences, where life scientists have come to depend upon the outstanding quality and reliability of our reagents. We have developed and manufactured a portfolio of more than 300 reagents and kits, many of them proprietary, for molecular biology, cell analysis and nucleic acid and protein separation and purification. Meridian operates under an ISO 13485 quality system and is one of the world's few manufacturers of ultra-pure dNTPs, as well as a variety of enzymes and biochemicals.

Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

As a nonprofit engineering innovation company, Draper serves our nation's interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers' needs and to deliver new capabilities to them.

Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression's OneRNA™ test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA's to approved therapies and clinical trials.

At Genospace, our mission is to deliver the platform that makes biomedical data useful and usable by everyone. Genospace has built a comprehensive platform for precision medicine to enable interpretation, analysis, reporting and collaboration on high-dimensional genomic and other biomedical data. With specific applications supporting research, development, pathology and clinical care, many of the most advanced precision medicine organizations are powered by Genospace. Please visit www.genospace.com for more information.

GNS Healthcare is a healthcare analytics company that specializes in precision medicine and biomedical research through advanced health data analysis.

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. IDRx’s lead program is IDRX-42, designed to inhibit key genetic drivers and drug-resistant mutations of KIT in gastrointestinal stromal tumor (GIST). IDRx's pipeline also includes a second KIT inhibitor, IDRX-73. Founded in 2021, IDRx’s leadership team has extensive experience in drug development and collectively has been involved in the discovery, development, and commercialization of more than 10 approved drugs. To learn more, please visit www.idrx.com.

Leveragen is a Boston-based biotech company specializing in genetic engineering. We develop comprehensive solutions for genetic modeling, creating designer mutations to study gene function and disease mechanisms. Currently, we are focused on engineering next-generation genetic models to enable the discovery of diverse biologic modalities, facilitating the development of novel diagnostics and therapeutics.

Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients. We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways.

Developing metabolomics assays and machine learning algorithms to produce “Biomarkers of Response” (BoR) that differentiate drug responders (R) from non-responders (NR).

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for rare and more prevalent neurological disorders. We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.

Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.

Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

Scorpion is a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer. We have built proprietary and fully-integrated discovery capabilities leveraging the most advanced technologies across cancer biology, medicinal chemistry and data sciences. Our current pipeline, led by our mutant-selective PI3Ka program STX-478, consists of three internally discovered clinical product candidates in addition to multiple discovery-stage programs. Our focus is on solving current gaps in therapeutic options for patients with cancer by discovering and developing exquisitely-selective product candidates against well-validated, previously undruggable targets to improve patient outcomes.

Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline. Sengenics is headquartered in the U.S. and has a worldwide network of offices, distributors, and service providers.

SeqLL is a biotechnology company that specializes in Quantitative RNA & Specialty DNA Sequencing, offering True Single Molecule Sequencing technology.

SYTE.bio is a Synthetic Biology Start-Up company developing precision DNA & RNA-based therapeutics and vaccines. The company has been incorporated as a Delaware C Corp in 2021 (SYTE.bio, Inc), and has labs & offices in Argentina's headquarter, that has been operating since 2017. SYTE.bio is pioneering the development of life-changing treatments for severe diseases and vaccines to treat and prevent diseases at the molecular and cellular level using engineered DNA, improving life through innovation. SYTE.bio’s powerful redosable DNA & RNA delivery platforms will unleash the potential of personalized genetic medicine in multiple potential applications, such as Gene Therapy (Oncology, Monogenic Diseases, Cardiovascular Diseases, Vaccines, Orphan Diseases), Cell Therapy (CAR-T Therapy, Induced Pluripotent Stem Cells (iPSC)) and Gene Editing (CRISPR/Cas, TALEN, ZFN).

Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact.

Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology. Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life. We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect. See more with us: www.variantyx.com/.

Velsera connects healthcare and life sciences to reveal the true promise of precision medicine — a continuous flow of knowledge between researchers, scientists, and clinicians around the world, fueling innovation and creating insights that radically improve human health. Our goal is to use data to radically improve healthcare globally and create value through multiomics and insights. If you’re interested in learning more about Velsera, please follow us and visit our website at velsera.com! Looking for someone to get in touch with? Please email hello@velsera.com